Atherosclerotic Cardiovascular Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Amgen Inc., Merck Sharp & Dohme Corp., NewAmsterdam Pharma

Atherosclerotic Cardiovascular Disease Market Size was highest in the US among the 7MM in the 2023, accounting for approximately USD 12 billion which is further expected to rise at a CAGR of 2.8% by 2034.
Atherosclerotic Cardiovascular Disease emerging therapies, such as Olpasiran (AMG 890), Obicetrapib (TA-8995), and others, are expected to boost the Atherosclerotic Cardiovascular Disease Market in the upcoming years.

DelveInsight has launched a new report on "Atherosclerotic Cardiovascular Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Atherosclerotic Cardiovascular Disease, historical and forecasted epidemiology as well as the Atherosclerotic Cardiovascular Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Atherosclerotic Cardiovascular Disease market report [https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Recent Breakthroughs and Market Developments in the Atherosclerotic Cardiovascular Disease Market:

*
In January 2025, the US Food and Drug Administration (FDA) granted 510(k) clearance for Roche's Tina-quant Registered Lipoprotein (a) Gen.2 Molarity assay-the first FDA-cleared blood test in the US to measure lipoprotein (a) [Lp(a)] levels in molar units. This assay supports the evaluation of lipid metabolism disorders and helps assess the risk of atherosclerotic cardiovascular disease (ASCVD) when used alongside clinical evaluations and other lipid tests.

*
Earlier, on August 28, 2024, Novartis announced that its Phase III V-MONO trial of Leqvio Registered (inclisiran) achieved its primary endpoints. The study showed that twice-yearly administration of Leqvio led to significant reductions in low-density lipoprotein cholesterol (LDL-C) compared with placebo and ezetimibe in patients with low to moderate ASCVD risk.

Some of the key facts of the Atherosclerotic Cardiovascular Disease Market Report:

*
In 2023, the Atherosclerotic Cardiovascular Disease (ASCVD) market size was the largest in the United States among the 7MM, reaching around USD 12 billion, and is projected to grow at a CAGR of 2.8% through 2034. The US also recorded the highest diagnosed prevalence, with nearly 26 million cases-approximately 14 million males and 11 million females, expected to rise further by 2034.

*
The ASCVD market is fueled by increasing disease prevalence, therapeutic innovations, and supportive government initiatives, though it continues to face challenges such as high treatment costs, stringent regulations, and adherence issues. Reimbursement frameworks emphasize preventive care and drug pricing negotiations. Key unmet needs include long-term disease management, improved access to advanced therapies, and personalized treatment options.

*
Current market therapies include statins, ezetimibe/bempedoic acid combinations, and PCSK9 inhibitors, contributing to a total 7MM market size of USD 23 billion in 2023. With the anticipated introduction of novel agents like Olpasiran, MK-0616, and Obicetrapib, the market is expected to expand at a CAGR of 2.2% over 2024-2034. In Japan, the ASCVD market was valued at USD 3 billion in 2023 and is projected to grow steadily through 2034.

Atherosclerotic Cardiovascular Disease Overview

Atherosclerotic Cardiovascular Disease (ASCVD) is a chronic, progressive disorder that can impact multiple arteries in the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and limbs (peripheral arteries). The primary forms of ASCVD include coronary artery disease (CAD), cerebrovascular disease (stroke), and peripheral arterial disease (PAD). Its development is driven by several risk factors such as unhealthy diet, physical inactivity, smoking, obesity, family history, and excessive alcohol consumption. While ASCVD often progresses silently in its early stages, symptoms emerge as arteries narrow and blood flow becomes restricted. The nature of symptoms depends on the affected arteries and the extent of blockage, with common signs including chest pain (angina), fatigue, dizziness, shortness of breath, palpitations, and cold sensations in the extremities.

Beyond symptomatic evaluation, ASCVD diagnosis also relies on risk assessment and clinical investigations. Genetic testing targeting APOE, LDLR, APOB, PCSK9, and LDLRAP1 variants, along with morphological imaging methods such as ultrasonography, CT, MRI/angiography, or catheterization, are commonly employed to confirm diagnosis. In cases where ASCVD is suspected, genetic and biomarker testing, combined with imaging, can provide diagnostic confirmation. However, the high cost and limited accessibility of genetic and biomarker testing remain key constraints.

Atherosclerotic Cardiovascular Disease Market Outlook

Treatment for Atherosclerotic Cardiovascular Disease (ASCVD) aims to lower cardiovascular risk and address the underlying atherosclerosis. Core management strategies involve lifestyle modifications-such as adopting a heart-healthy diet, engaging in regular physical activity, quitting smoking, and maintaining a healthy weight-to effectively control major risk factors like hypertension, diabetes, and hyperlipidemia.

Pharmacologic intervention plays a central role, with statins serving as the first-line therapy for reducing low-density lipoprotein cholesterol (LDL-C). High-intensity statins are typically prescribed for patients at elevated risk. For individuals who are statin-intolerant or do not achieve target LDL-C levels, additional agents such as ezetimibe or PCSK9 inhibitors may be introduced. Antiplatelet therapy, most commonly with aspirin, is used to prevent thrombotic events in patients with established ASCVD. Managing blood pressure through antihypertensive medications-such as ACE inhibitors or ARBs-is also vital to reduce cardiovascular complications. In more severe cases, such as acute coronary syndrome or significant coronary artery narrowing, revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) are often required.

Discover how the Atherosclerotic Cardiovascular Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Atherosclerotic Cardiovascular Disease Marketed Drugs

*
LEQVIO (inclisiran): Novartis Pharmaceuticals Corporation

*
PRALUENT (alirocumab): Regeneron Pharmaceuticals/Sanofi

Atherosclerotic Cardiovascular Disease Emerging Drugs

*
Olpasiran (AMG 890): Amgen Inc.

*
Obicetrapib (TA-8995): NewAmsterdam Pharma

Scope of the Atherosclerotic Cardiovascular Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Atherosclerotic Cardiovascular Disease Companies: Amgen Inc., Merck Sharp & Dohme Corp., NewAmsterdam Pharma, and others

*
Key Atherosclerotic Cardiovascular Disease Therapies: Dazukibart (PF-06823859), and others

*
Atherosclerotic Cardiovascular Disease Therapeutic Assessment: Atherosclerotic Cardiovascular Disease current marketed and Atherosclerotic Cardiovascular Disease emerging therapies

*
Atherosclerotic Cardiovascular Disease Market Dynamics: Atherosclerotic Cardiovascular Disease market drivers and Atherosclerotic Cardiovascular Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Atherosclerotic Cardiovascular Disease Unmet Needs, KOL's views, Analyst's views, Atherosclerotic Cardiovascular Disease Market Access and Reimbursement

To know what's more in our Atherosclerotic Cardiovascular Disease report, visit: https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Atherosclerotic Cardiovascular Disease Market Report:

*
Atherosclerotic Cardiovascular Disease market report covers a descriptive overview and comprehensive insight of the Atherosclerotic Cardiovascular Disease Epidemiology and Atherosclerotic Cardiovascular Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Atherosclerotic Cardiovascular Disease market report provides insights into the current and emerging therapies.

*
The Atherosclerotic Cardiovascular Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Atherosclerotic Cardiovascular Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Atherosclerotic Cardiovascular Disease market.

Got queries? Click here to know more about the Atherosclerotic Cardiovascular Disease market Landscape [https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Atherosclerotic Cardiovascular Disease Patient Share (%) Overview at a Glance

5. Atherosclerotic Cardiovascular Disease Market Overview at a Glance

6. Atherosclerotic Cardiovascular Disease Disease Background and Overview

7. Atherosclerotic Cardiovascular Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Atherosclerotic Cardiovascular Disease

9. Atherosclerotic Cardiovascular Disease Current Treatment and Medical Practices

10. Unmet Needs

11. Atherosclerotic Cardiovascular Disease Emerging Therapies

12. Atherosclerotic Cardiovascular Disease Market Outlook

13. Country-Wise Atherosclerotic Cardiovascular Disease Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Atherosclerotic Cardiovascular Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Atherosclerotic Cardiovascular Disease Market Outlook 2034 [https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Atherosclerotic Cardiovascular Disease Pipeline Insights, DelveInsight

"Atherosclerotic Cardiovascular Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Atherosclerotic Cardiovascular Disease market. A detailed picture of the Atherosclerotic Cardiovascular Disease pipeline landscape is provided, which includes the disease overview and Atherosclerotic Cardiovascular Disease treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atherosclerotic-cardiovascular-disease-market-epidemiology-therapies-companies-delveinsight-amgen-inc-merck-sharp-dohme-corp-newamsterdam-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.